SEOVF (Sernova Biotherapeutics) ROCE % : 0.00% (As of Oct. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sernova Biotherapeutics's annualized ROCE % for the quarter that ended in Oct. 2024 was 0.00%.

Sernova Biotherapeutics ROCE % Historical Data

The historical data trend for Sernova Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics ROCE % Chart

Sernova Biotherapeutics Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

ROCE %

Get a 7-Day Free Trial

-107.50

-41.98

-61.57

-129.15

-93,751.02

Sernova Biotherapeutics Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-255.12	-468.15	-	-	-

Sernova Biotherapeutics ROCE % Calculation

Sernova Biotherapeutics's annualized ROCE % for the fiscal year that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2024 )		(A: Oct. 2023 )		(A: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2024 )		(A: Oct. 2023 )		(A: Oct. 2024 )
	=	-22.969	/	( ( (16.122 - 6.995)	+	(5.471 - 14.549) )	/ 2 )
	=	-22.969	/	( (9.127	+	-9.078)	/ 2 )
	=	-22.969	/	0.0245
	=	-93,751.02 %

Sernova Biotherapeutics's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-13.844	/	( ( (5.437 - 14.226)	+	(5.471 - 14.549) )	/ 2 )
	=	-13.844	/	( ( -8.789	+	-9.078 )	/ 2 )
	=	-13.844	/	-8.9335
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

Sernova Biotherapeutics (OTCPK:SEOVF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sernova Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PSH0:Germany SVA:Canada

Address

700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.